0001562180-24-005245.txt : 20240624
0001562180-24-005245.hdr.sgml : 20240624
20240624160117
ACCESSION NUMBER: 0001562180-24-005245
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240621
FILED AS OF DATE: 20240624
DATE AS OF CHANGE: 20240624
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Cavalie Fanny
CENTRAL INDEX KEY: 0001913484
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39634
FILM NUMBER: 241064198
MAIL ADDRESS:
STREET 1: C/O FOGHORN THERAPEUTICS INC.
STREET 2: 500 TECHNOLOGY SQUARE, SUITE 700
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Foghorn Therapeutics Inc.
CENTRAL INDEX KEY: 0001822462
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 500 TECHNOLOGY SQUARE
STREET 2: SUITE 700
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-586-3100
MAIL ADDRESS:
STREET 1: 500 TECHNOLOGY SQUARE
STREET 2: SUITE 700
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0508
4
2024-06-21
true
0001822462
Foghorn Therapeutics Inc.
FHTX
0001913484
Cavalie Fanny
500 TECHNOLOGY SQUARE
STE #700
CAMBRIDGE
MA
02139
false
true
false
false
Chief Strategy/Bus Ops Officer
false
Common Stock
86992.00
D
Stock Options (Right to buy)
0.73
2028-03-27
Common Stock
5575.00
5575.00
D
Stock Options (Right to buy)
3.72
2029-02-12
Common Stock
10135.00
10135.00
D
Stock Options (Right to buy)
8.77
2030-08-17
Common Stock
59459.00
59459.00
D
Stock Options (Right to buy)
16.63
2031-01-27
Common Stock
50000.00
50000.00
D
Stock Options (Right to buy)
14.87
2032-01-25
Common Stock
125000.00
125000.00
D
Stock Options (Right to buy)
8.38
2033-01-25
Common Stock
65000.00
65000.00
D
Stock Options (Right to buy)
3.06
2034-01-23
Common Stock
80000.00
80000.00
D
The option vested as to 25% of the underlying shares of common stock on March 19, 2019, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter.
The option vested as to 25% of the underlying shares of common stock on January 30, 2020, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter.
The option vested as to 25% of the underlying shares of common stock on August 18, 2021, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter.
The option vested as to 25% of the underlying shares of common stock on January 28, 2022, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter.
The option vested as to 25% of the underlying shares of common stock on January 26, 2023, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter.
The option vested as to 25% of the underlying shares of common stock on January 26, 2024, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter.
The option vests as to 25% of the underlying shares of common stock on January 24, 2025, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter.
Exit Form 4 filed solely to report the Reporting Person is no longer an officer of the Issuer within the meaning of Rule 16a-1 of the Securities Exchange Act of 1934, as amended.
/s/ Michael LaCascia, Attorney-in-Fact for Fanny Cavalie
2024-06-24